ReviewGenome medicine2019
The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy.
Review in Genome medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The Black Hole of Immune Checkpoint Blocking Therapy for Gastric Cancer: Hyperprogressive Disease.Cancer science · 2025Review
- Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors.Journal of neuro-oncology · 2025Article
- Case Report: Exploring delayed hyperprogressive disease: a case study of post-immunotherapy in lung cancer.Frontiers in immunology · 2025Article
- PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- TMEM173 is a biomarker of predicting prognosis, immune responses and therapeutic effect in human lung adenocarcinoma.Discover oncology · 2024Article
- Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB.Scientific reports · 2022Article
- Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review.Translational lung cancer research · 2021Review
- Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single-center experience.Cancer medicine · 2021Article
- Identifying key questions in the ecology and evolution of cancer.Evolutionary applications · 2021Article
- Emerging concepts in PD-1 checkpoint biology.Seminars in immunology · 2021Review
- TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model.PloS one · 2021Article
- Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes.Journal for immunotherapy of cancer · 2020Article
- Review
- MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma.Cancers · 2020Article
- Editorial: Lymphocyte Functional Crosstalk and Regulation.Frontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Immune checkpoint blockade therapy can elicit robust and durable responses in a variety of cancer types. While many patients do not respond, recent reports highlight a distinct group of patients whose tumors undergo rapid growth, leading to progressive disease and poor outcome. In this perspective, we synthesize and summarize some important issues surrounding hyperprogression, defining characteristics, prognostic implications, and controversies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.